These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 1969293

  • 1. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
    Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM.
    Blood; 1990 Apr 01; 75(7):1455-9. PubMed ID: 1969293
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
    Mehta JL, Nichols WW, Saldeen TG, Chandna VK, Nicolini FA, Lawson DL, ter Riet MF.
    J Cardiovasc Pharmacol; 1990 Jul 01; 16(1):112-20. PubMed ID: 1696653
    [Abstract] [Full Text] [Related]

  • 4. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Jul 01; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 5. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW, Nicolini FA, Khan S, Saldeen TG, Mehta JL.
    Am Heart J; 1993 Aug 01; 126(2):285-92. PubMed ID: 7687816
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun 01; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 8. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb 01; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 9. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 01; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadváry P.
    J Pharmacol Exp Ther; 1993 Jan 01; 264(1):501-8. PubMed ID: 8423548
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 01; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 15. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
    Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M.
    Circulation; 1990 Mar 01; 81(3):1115-22. PubMed ID: 1689620
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep 01; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 18. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar 01; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 19. Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
    Rebello SS, Huang J, Saito K, Saucedo JF, Bates ER, Lucchesi BR.
    Eur J Pharmacol; 1999 Jun 25; 374(3):399-410. PubMed ID: 10422784
    [Abstract] [Full Text] [Related]

  • 20. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Komjathy SF, Poulton J, Stafford JL, Godard J.
    Circulation; 1994 Jan 25; 89(1):361-5. PubMed ID: 8281671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.